Brokerages remained upbeat on Vedanta Ltd. and Piramal Pharma Ltd. this Tuesday. Citi Research maintained a ‘buy’ rating on Vedanta despite its high dividend outflows, highlighting steady cash inflows from Hindustan Zinc Ltd.
Meanwhile, JM Financial initiated coverage on Piramal Pharma with a ‘buy’ rating, projecting robust growth in the Contract Development and Manufacturing Organisation segment and margin expansion over the next three years.
NDTV Profit tracks what brokerages are putting out on stocks and sectors. Here are all the top calls from analysts you need to know about on Tuesday.
